Armando Sardi, MD
Dr. Armando Sardi is an internationally respected surgical oncologist and the Medical Director of The Institute for Cancer Care at Mercy in Baltimore, Maryland. He specializes in the treatment of abdominal and peritoneal surface cancers, including malignant peritoneal mesothelioma, and is one of the leading experts in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) for its treatment.[1]
Dr. Sardi is determined to provide each patient with the opportunity to overcome their illness, and this has resulted in patients diagnosed with late-stage malignancies traveling from points up and down the East Coast, as well as from across the United States and the world, to seek out his expertise and surgical skill.
Education and Career
Dr. Sardi earned his medical degree at the Universidad del Valle in Cali, Columbia, then completed his internship and residency in Surgery at Ascension Saint Agnes Hospital in Baltimore, Maryland. He completed a Surgical Oncology fellowship at Ohio State University Hospital.[1]
Dr. Sardi is also a National Cancer Institute Clinical Investigator. He has conducted vital research leading to breakthroughs in the aggressive management of complex cancers and has authored more than 120 medical publications. He is a highly respected authority on various topics in complex surgical oncology techniques and is frequently invited to speak to both national and international audiences.
Professional Memberships and Activities
In addition to his role at The Institute for Cancer Care at Mercy, Dr. Sardi provides medical care in Columbia, South America through the non-profit organization, Partners for Cancer Care and Prevention. In recognition of this work, he has been recognized in Colombia, South America as one of the 100 Most Influential Expatriates This organization was the recipient of the Conquer Cancer Foundation’s Inaugural International Innovation Grant. Additionally, Dr. Sardi was named to a list of “Medical Geniuses that Make Colombia Proud” in La Nota Económica – a Colombian economic analysis magazine.[1]
Dr. Sardi is also an active member of numerous professional organizations, including:[1]
- American College of Surgeons
- Society of Surgical Oncology
- American Society of Clinical Oncology
- The Society for Surgery of the Alimentary Tract
- Medical and Chirurgical Faculty of Maryland
- Southeastern Surgical Association
- American Medical Association
- Association of the Alumni of the “Division de Salud of the Universidad del Valle
- National Cancer Institute – Clinical Investigator
Research
Dr. Sardi’s primary research focus is on increasing awareness of and reporting on The Institute for Cancer Care at Mery’s experience with cytoreductive surgery with HIPEC. Their work centers on data abstraction, analysis, and writing for the development of manuscripts for publication in major medical journals and on presentations at national and international symposiums. Under his leadership, physicians associated with the program have presented in both the United States and in Europe and have published over 20 manuscripts in medical journals.[2]
Ongoing clinical trials include:[2]
Topic: Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Short Name: Ovarian HIPEC
A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy with carboplatin and paclitaxel as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer
Clinical Trials ID #: NCT02124421
2) Topic: Appendiceal Cancer
Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication with Antibiotic Treatment on the Long Term Outcomes of Patients with Pseudomyxoma Peritonei of appendiceal origin undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
Clinical Trials ID #: NCT02387203
3) Topic: Appendiceal Cancer, Gastrointestinal Microbiome
A cohort study of the gastrointestinal microbiome in appendiceal cancer with peritoneal spread.
Clinical Trials ID #: NCT02599116
Other areas of research interest include peritoneal mesothelioma, thyroid cancer, gynecologic malignancies, neuroendocrine tumors, and melanomas.
His recent publications include:[3]
- ASO Visual Abstract: Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix. Lopez-Ramirez F, Sardi A, King MC, Nikiforchin A, Falla-Zuniga LF, Barakat P, Nieroda C, Gushchin. Ann Surg Oncol. 2024 Jan 07;():doi: 10.1245/s10434-023-14845-x
- Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer. Nikiforchin A, Sardi A, King MC, Baron E, Lopez-Ramirez F, Falla-Zuniga LF, Barakat P, Iugai S, Pawlikowski K, Nieroda C, Campbell K, Ryu H, Diaz-Montes T, Gushchin. Eur J Surg Oncol. 2024 Jan 02;50(2):107948. doi: 10.1016/j.ejso.2023.107948
- Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix. Lopez-Ramirez F, Sardi A, King MC, Nikiforchin A, Falla-Zuniga LF, Barakat P, Nieroda C, Gushchin. Ann Surg Oncol. 2023 Dec 28;():doi: 10.1245/s10434-023-14683-x
- ASO Author Reflections: Leave No Stone Unturned-Confidently Ruling Out Metastatic Lymph Node Disease in Appendix Cancer. Lopez-Ramirez F, King MC, Sardi A, Gushchin. Ann Surg Oncol. 2023 Dec 10;():doi: 10.1245/s10434-023-14773-w
- ASO Visual Abstract: Patterns of Recurrence in Appendix Cancer After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Nikiforchin A, Sardi A, King MC, Baron E, Lopez-Ramirez F, Falla-Zuniga LF, Barakat P, Iugai S, Pawlikowski K, Nieroda C, Gushchin. Ann Surg Oncol. 2023 Nov ;30(12):7874-7875. doi: 10.1245/s10434-023-14236-2
